{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000003","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.160273+00:00","generated_at":"2026-06-07T04:13:57.471173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris expects Q4 cashflow positive, 2023 revenue at high end of $160M-$165M","bullets":["Total revenue for FY 2023 expected at high end of prior $160M-$165M guidance.","Ending cash, equivalents & short-term investments >$72M, above $65M-$70M guidance.","Q4 2023 expected to be cashflow positive; Q4 & FY results on or about March 6, 2024.","2024 outlook: revenue growth, flat opex, declining burn, sufficient cash for obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000003","json":"https://secwatch.observer/filing/0001867096-24-000003.json","markdown":"https://secwatch.observer/filing/0001867096-24-000003.md","text":"https://secwatch.observer/filing/0001867096-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/0001867096-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/xers-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:13:57.471173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"486398c10e3a6007f17ac7489e87e9cc5e15d87d","claim":"Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On January 4, 2024, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release announcing certain preliminary results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/0001867096-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}